- Trial phase
- Preclinical / Early-stage (no clinical trials identified)
- Time to market
- Unknown, likely years away, if ever developed. The company's lead asset fasedienol just failed a Phase 3 trial, and with only ~$31.7M in cash (as of June 30, 2026) burning ~$13.7M/quarter, Vistagen may not have the resources to advance itruvone into the clinic without significant financing.
- Why 2/10
- Itruvone has no scheduled clinical readout, PDUFA, or other hard binary catalyst within the next ~12 months. It is a preclinical/early-stage pipeline asset at a company with a ~$10M market cap whose lead drug (fasedienol) just failed Phase 3. Itruvone is too early-stage and too small a part of an already-struggling pipeline to drive a material share-price move on its own.
Itruvone is not a tradeable catalyst, it is a preclinical pipeline placeholder at a cash-strapped micro-cap whose lead asset just failed Phase 3. VTGN stock will move on the outcome of the FDA meeting for fasedienol and on financing events, not on itruvone. Avoid trading based on itruvone alone.
Price Chart
Executive Summary
Itruvone is an early-stage pipeline drug at Vistagen Therapeutics (VTGN), a micro-cap biotech trading around $0.24/share with a ~$10M market cap. The drug is mentioned in SEC filings alongside fasedienol (the company's now-failed Phase 3 social anxiety drug) and refisolone, but no mechanism, indication, clinical trial data, or development timeline has been publicly disclosed. Vistagen is in a precarious financial position with ~$31.7M in cash burning ~$13.7M/quarter after its lead asset fasedienol failed the PALISADE-4 Phase 3 trial in June 2026. Itruvone is too early-stage and too thinly documented to be a meaningful standalone value driver for the stock.
How It Works
Not publicly disclosed. Itruvone is an early-stage pipeline asset at Vistagen Therapeutics, alongside the company's former lead drug fasedienol (a pherine nasal spray for social anxiety disorder) and refisolone. No specific mechanism, indication, or molecular target has been publicly described for itruvone.
Trial Status
Itruvone is listed as a pipeline drug in Vistagen's SEC filings alongside fasedienol and refisolone, but no clinical trials, regulatory filings, or development-stage details are publicly available. The drug appears to be at a very early preclinical stage. No ClinicalTrials.gov records, FDA catalysts, or press releases specifically mentioning itruvone were found in SecBot's ingested databases.
The Two-Sided Case
Upcoming Catalysts
- No scheduled catalysts identified for itruvone specifically. The company's next major event is an FDA meeting to discuss a potential path forward for fasedienol following its Phase 3 failure.
Source Filing
The SecBot filing or press-release report that triggered this drug report:
Vistagen Therapeutics, Inc. PRESS-RELEASE VTGN ·Originating report